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Abstract 
Review on CLEC1B, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: 1810061I13Rik, CLEC2, CLEC2B, 
PRO1384, QDED721 
HGNC (Hugo): CLEC1B 
Location: 12p13.2 
DNA/RNA 
Description 
The gene is 982 bp in length and contains six 
exons. 
Transcription 
In human, mouse, rabbit, rat, and bovine species, 
transcription produces 2-4 different mRNAs, 
including alternatively spliced variants and 1 
unspliced form. 
Pseudogene 
No known pseudogenes. 
Protein 
Description 
CLEC-2 is a 32-kDa (229 amino acids) type II 
trans-membrane receptor that belongs to C-type 
lectin superfamily. CLEC-2 has 1 C-type lectin-like  
domain (CTLD) and belongs to the non-classical C-
type lectins, which contain a CTLD homologous to 
a carbohydrate recognition domain but lack the 
consensus sequence for binding sugars and calcium 
(Colonna et al., 2000). CLEC-2 has a YxxL motif 
in its cytoplasmic tail, which is crucial for CLEC-2-
mediated signal transduction. This sequence is 
called hemi-ITAM, since it resembles the 
immunoreceptor tyrosine-based activation motif 
(ITAM, YxxL-(X)10-12-YxxL), which includes 2 
YxxL motifs. CLEC-2 was first identified through a 
bioinformatic screen for C-type lectin-like 
molecules with immune functions. The gene 
encoding human CLEC-2 is located in the natural 
killer complex on chromosome 12 along with other 
C-type lectin-like receptors, including NKG2D, 
LOX-1, and Dectin-1 (Sobanov et al., 2001). 
Expression 
Organ: Highly expressed in bone marrow and 
slightly expressed in liver. 
Cell types: CLEC-2 protein is expressed at high 
levels in platelets/megakaryocytes and at low levels 
in sinusoidal endothelial cells (Chaipan et al., 2006) 
and Kupffer cells (Tang et al., 2010) in humans. In 
mice, CLEC-2 protein is highly expressed in 
platelets/megakaryocytes, and is slightly expressed 
in other blood cells, including neutrophils, 
monocytes, dendritic cells, NK cells, B cells 
(Chang et al., 2010; Mourao-Sa et al., 2011), and 
Kupffer cells (Tang et al., 2010). 
Localisation 
Plasma membrane. 
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Schematic representation of the domain structure of CLEC-2. TM represents transmembrane region. Neck represents neck 
region. CTLD represents C-type lectin-like domain (Colonna et al., 2000; Watson et al., 2007; Wang et al., 2012). 
 
 
Function 
Separation of blood and lymphatic vessels 
during development 
Podoplanin is also expressed on the surface of 
lymphatic endothelial cells, but not vascular 
endothelial cells. During organ development, a 
cluster of endothelial cells in the cardinal vein is 
committed to the lymphatic phenotype, and sprouts 
to form the primary lymphatic sacs from which a 
portion of the peripheral lymphatic vasculature is 
generated by further centrifugal growth (Tammela 
and Alitalo, 2010).  
At this stage, platelets are activated by an 
association between CLEC-2 in the platelets and 
podoplanin in the lymphatic endothelial cells, 
which inhibits the growth and migration of 
lymphatic endothelial cells and facilitates the 
separation of blood and lymphatic vessels. 
CLEC-2-deficient mice show blood-filled 
lymphatic vessels and severe edema due to 
lymphatic dysfunction (Bertozzi et al., 2010; 
Suzuki-Inoue et al., 2010; Finney et al., 2011).  
One controversial theory proposes that granule 
contents released from activated platelets inhibit the 
function of lymphatic endothelial cells (Osada et 
al., 2012). 
Thrombus formation 
Thrombus formation under flow conditions has 
been reported to be impaired in CLEC-2-deficient 
blood. In vivo thrombus formation is also inhibited 
in antibody-induced CLEC-2-deficient mice (May 
et al., 2009) or bone marrow chimeric mice 
deficient in CLEC-2 (Suzuki-Inoue et al., 2010). 
These findings suggest that CLEC-2 is involved in 
the stabilization of thrombus formation under flow 
conditions, although the precise mechanism by 
which this occurs has not yet been elucidated. 
Combined in vivo depletion of CLEC-2 and 
glycoprotein VI (GPVI), a collagen receptor in  
platelets, severely compromises haemostasis and 
abrogates arterial thrombosis in mice (Bender et al., 
2013). CLEC-2 and GPVI, both of which generate 
activation signals depending on ITAMs and 
tyrosine kinases, play a complementary role in 
thrombosis and haemostasis. 
Maintenance of vascular integrity 
CLEC-2 is involved in maintaining vascular 
integrity in inflammation (Boulaftali et al., 2013) 
and high endothelial venules (HEVs) in lymph 
nodes upon lymphocyte transmigration (Herzog et 
al., 2013). Podoplanin is expressed on fibroblastic 
reticular cells, which surround HEVs.  
Upon lymphocyte transmigration, platelets 
extravasate to the perivenular space of HEVs and 
interact with podoplanin.  
Local release of sphingosine-1-phosphate after 
CLEC-2-podoplanin-mediated platelet activation is 
critical for HEV integrity during immune 
responses. 
Antigen presentation 
CLEC-2 is also expressed in dendritic cells (DCs) 
in mice. Associations between CLEC-2 in DCs and 
podoplanin in lymphatic endothelial and 
fibroblastic reticular cells in the lymph nodes 
facilitates DC entry into the lymphatics as well as 
movement to and within the lymph nodes, thereby 
reducing T cell priming.  
CLEC-2 engagement of podoplanin was found to 
be necessary for DCs to spread and migrate along 
stromal surfaces, and was sufficient to induce 
membrane protrusions through Vav and Rac1 
activation (Acton et al., 2012). 
HIV transmission 
Previous reports indicate that platelets capture and 
transfer infectious HIV-1 via DC-SIGN and CLEC-
2, possibly facilitated HIV-1 dissemination in 
infected patients (Suzuki-Inoue et al., 2011). 
CLEC-2 does not directly bind to the viral envelope 
proteins, but to podoplanin incorporated into the 
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HIV particles released from HEK-293T cells 
(Chaipan et al., 2010).  
This mechanism does not seem to be important for 
viral dispersion in vivo since podoplanin is not 
expressed on T cells, which are the major HIV 
target. 
Phagocytosis and cytokine production 
CLEC-2 is expressed in dendritic cells, NK cells, B 
cells, neutrophils, and monocytes, in addition to 
platelets (Kerrigan et al., 2009; Chang et al., 2010; 
Mourao-Sa et al., 2011). Murine CLEC-2 in 
neutrophils mediates the phagocytosis of anti-
CLEC-2 antibody-coated beads. Moreover, 
neutrophils stimulated by rhodocytin produce 
proinflammatory cytokines such as TNF-α 
depending on CLEC-2, but not respiratory burst 
(Kerrigan et al., 2009). CLEC-2 ligation in 
macrophages and DCs selectively up-regulates 
production of IL-10, an anti-inflammatory cytokine, 
by Toll-like receptor stimulation. Although the 
physiological relevance of these phenomena has not 
been determined, CLEC-2 is expressed in myeloid 
cells and may be able to modulate the inflammatory 
response in vivo. 
Homology 
Among 226-229 amino acids of 5 species' (human, 
mouse, rat, rabbit, and bovine) CLEC-2, there are 
129 positions with 100% sequence conservation, 36 
positions with 80% sequence conservation, and 44 
positions with 60% sequence conservation. Human 
CLEC-2 is 62% identical to mouse CLEC-2, and 
70% to rabbit CLEC-2. 
Mutations 
Note 
No known mutations. 
Implicated in 
Haematogenous tumour metastasis 
Note 
CLEC-2 has been identified as a receptor for a 
platelet activating snake venom, rhodocytin 
(Suzuki-Inoue et al., 2006). Podoplanin is a type I 
transmembrane sialomucin-like glycoprotein, and is 
identified as the endogenous ligand for CLEC-2 
(Suzuki-Inoue et al., 2007; Christou et al., 2008). It 
is expressed on the surface of certain types of 
tumour cells, where it causes aggregation of 
platelets in the blood stream, facilitating 
haematogenous tumour metastasis. Platelet 
aggregation surrounding tumour cells is considered 
to protect the tumour cells from shear stress and 
NK cells (Nieswandt et al., 1999) in the blood 
stream and provide scaffolding for tumour cell 
nests. Growth factors released from activated 
platelets stimulate angiogenesis and/or tumour 
growth. In an experimental model of metastasis in 
mice, an anti-podoplanin blocking antibody 
significantly inhibited the number of tumour-cell 
containing metastatic lung nodules that expressed 
podoplanin, implying that CLEC-2/podoplanin may 
be a promising target protein for anti-metastatic 
drugs (Kato et al., 2008). 
Various diseases 
Note 
No implication in any specific diseases in human 
has been reported. 
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